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second UNAIDS 90-90-90 targets in adolescents.
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Medicine. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).HIV/AIDS is the second most frequent cause of death for ad-
olescents aged 10e19 years globally and the leading cause of
death in Sub-Saharan Africa (SSA) [1]. Adolescent deaths are
largely due to attrition throughout the HIV care cascade: low
knowledge of HIV status, delayed linkage to care (LTC) and up-
take of antiretroviral therapy (ART), low retention and adherence
to ART, and, therefore, poor viral suppression [2].
The “HIV care cascade,” also known as the HIV care contin-
uum, outlines the sequential steps of HIV care from the initial
diagnosis to the goal of viral suppression [3,4]. When compared
with adults, evidence suggests that adolescents living with HIV
(ALHIV) are less likely to know their HIV status, are more likely to
be lost to follow-up after registering for HIV care, have subopti-
mal adherence to ART, experience higher rates of virologic fail-
ure, and have worse outcomes across the cascade [5].
With dropouts at each stage of the cascade, low proportions
of ALHIV achieve viral suppression, which is problematic for
current prevention approaches [6,7]. To achieve UNAIDS 90-
90-90 targets for adolescents, we need to accurately measure
progress in routine “test and treat” settings and implement in-
terventions, which reduce dropouts along the cascade. However,
we have limited data on the HIV care cascade among adolescents
living in SSA [2,8,9].
The HPTN 071 (PopART) trial was a three-arm community
randomized trial in 12 communities in Zambia and nine in South
Africa (SA) evaluating the impact of a combination HIV preven-
tion package, including universal HIV testing and treatment, on
community-level HIV incidence [10,11]. Within this trial was a
substudy called PopART for Youth (P-ART-Y), which evaluated
the acceptability and uptake of the PopART HIV prevention
package among young people (YP) with a special focus on ado-
lescents aged 10e19 years [12]. It also assessed the need for
specific youth-targeted interventions in the context of
community-wide universal HIV testing and treatment.
We have previously reported on uptake of testing among
adolescents aged 15e19 years from four communities in Zambia
during the first 11 months of the P-ART-Y study from October
2015 to September 2016 [12]. Here we report on the HIV care
cascade after the addition of youth-targeted interventions for
adolescents aged 10e19 years from 14 communities in Zambia
and SA, during the period September 2016 to December 2017.We
highlight the main successes and gaps in the cascade and
disaggregate the data by country, sex, and age.Methods
Trial design and setting
The HPTN 071 (PopART) trial was a three-arm community
randomized trial implemented in 21 communities in Zambia and
SA [10,11]. The 21 communities were divided into sevenmatched
triplets (four triplets in Zambia and three in SA), within which
communities were similar in geography, size, and estimated HIV
prevalence at the start of the trial. Communities in each triplet
were randomly assigned to one of three arms: Arm A receivingthe full PopART intervention including universal HIV testing and
ART for people living with HIV regardless of CD4 count, Arm B
receiving the full PopART intervention with ART provided ac-
cording to national guidelines, and Arm C being the standard of
care. Between April and October 2016, national guidelines for
initiating ART were changed in both countries, to start ART
regardless of CD4 count; therefore, the intervention in Arms A
and B became identical during this analysis period. Further de-
tails of the PopART trial are described elsewhere [10].
The P-ART-Y study had three phases: qualitative baseline
studies and collection of process data from the PopART trial
(Phase 1); addition of youth-targeted interventions (Phase 2);
and a cross-sectional survey to determine the effect of the
intervention on knowledge of HIV status among adolescents
(Phase 3; Appendix 1).The study intervention
The PopART combination HIV prevention package was deliv-
ered by trained community health workers called community
HIV care providers (CHiPs) via a door-to-door approach, with
treatment and care services provided by local government clinics
[10]. The CHiPs delivered the intervention over 4 years
(November 2013 to December 2017) in three rounds (R1e3) of
which they visited all households, offered to explain the inter-
vention, and asked permission to enumerate (list) all household
members, providing a count of all individuals in the commu-
nities. CHiPs enumerated all householdmembers including those
absent, irrespective of age. The P-ART-Y study was implemented
during R2 (July 2015 to August 2016) and R3 (September 2016 to
December 2017) of the PopART intervention (Appendix 1).
CHiPs also offered HIV counseling and testing services (HTS) to
all eligible householdmembers, supported LTC for all people living
with HIV, and provided ongoing ART adherence support, condom
promotion and provision, screening for tuberculosis and sexually
transmitted infections, and referrals to voluntary medical male
circumcision for HIV-negative men. They worked in pairs within
an allocated zone (consisting of 350e500 households) of a
community and arranged repeat household visits to monitor LTC
services and offer HTS for those absent at previous visits.Informed consent
To take part in the intervention, all household members aged
18 years were asked for verbal informed consent, whereas
those <18 years were asked for their verbal assent and their
parents or guardians (head of household or appropriate
responsible adult) for their verbal consent. For child-headed
households, informed consent was given by the head of the
household. If verbal consent was obtained, the individual was
considered a study participant. Written consent for HIV testing
was sought in adolescents aged 16 years in Zambia and those
aged 12 years in SA, with parental written consent needed for
adolescents below those ages, as per national guidelines.
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Youth-targeted interventions were implemented in July 2016
(approximately a year after beginning of R2) and throughout R3
to increase participation, HIV testing uptake, and LTC. Thesewere
offered in Arms A and B in addition to the PopART intervention
(Appendices 1 and 2). Interventions included the employment of
youth counselors, training parents, and clinic staff to enable
them to engage better with adolescents and reinforcing HIV
prevention school-based activities. Youth-friendly corners
received financial and/or technical support so that they could be
transformed into hubs where adolescents could be mentored
and supported by peers and where educational materials and
condoms were distributed.
Adolescents aged 10e14 years were screened for risk of HIV
infection using a screening tool based on four questions [13]:
1. Has the child ever been admitted to hospital?
2. Does the child have recurring skin problems?
3. Are one or both parents of the child deceased?
4. Has the child had poor health in the past 3 months?
If the answer was yes to one or more of these questions, the
adolescent was classified as “at risk.” Adolescents classified as “at
risk” and those aged 15 years were prioritized by CHiPs to be
tested for HIV.Data collection and analysis
We report on adolescents aged 10e19 years from 14 inter-
vention (Arms A and B) communities in Zambia and SA, covering
the period September 2016 to December 2017 (R3) of the PopART
intervention. The proportions of key indicators (uptake of HIV
testing, knowledge of HIV status, ART coverage, time to initiate
ART, and retention on ART) are disaggregated by country, sex,
and age group. The analysis was limited to R3 because (1) in R1,
we did not have ethics permission to collect data from those aged
<18 years; (2) data had previously been published from four of
the Zambian communities in the first year of the P-ART-Y study
[14]; and (3) reliable data were not available from SA in the
previous rounds [15].
All analyses were repeated separately for Arms A and B to
investigate whether any stark differences could help explain the
final PopART trial results [15,16]. In the PopART trial, HIV inci-
dence differed quite substantially between Arms A and B, with
Arm B having a lower incidence than Arm A (despite Arm A
having the slightly more intensive intervention for the early
period of the study). In addition, formal statistical testingwas not
done due to the large sample sizes involved, and small p values
could be obtained for even marginal differences.
An adolescent was classified as knowing their HIV status
before the R3 intervention if they self-reported living with HIV
(LHIV) or self-reported to have tested HIV negative in the pre-
vious 12 months. After the R3 visit, those who received an HIV
test and a result from a CHiP were classified as knowing their HIV
status, along with those who had self-reported LHIV. ART
coverage was measured as the proportion of ALHIV who self-
report currently being on ART and also report having not
missed their pills in the last 3 days. ART retentionwas defined as
the proportion who were currently on ART and report notmissing any pills in the last 3 days, among those who report ever
having started ART.
Self-reported data were collected on whether they were
registered for HIV care, had ever taken ART, were currently on
ART, and for those who reported taking ART howmany pills they
had missed in the previous 3 days. For adolescents who reported
they were registered for HIV care, CHiPs asked to see their ART
card fromwhich the ART card number and date of ART initiation
were recorded.
To estimate the time it took to initiate ART after a referral, the
R3 data were combined with the R2 data to provide sufficient
follow-up time. KaplaneMeier plots were used to estimate the
median time from first referral to ART initiation, using the date
the participant was referred to HIV care by the CHiPs as the start
of the observation period. Cox regression was used to assess
whether time to ART initiation differed by sex or age group,
adjusted for age, sex, and trial arm. Data were censored on the
date of the last follow-up visit for those who never started ART,
and follow-up data up to December 2017 were used.
The coverage against the first two of the UNAIDS 90-90-90
targets (proportion of ALHIV who knew their status and pro-
portion of those who were on ART) was estimated, with
extrapolation to the total adolescent population. Definitions and
assumptions required for extrapolating these estimates to the
whole adolescent population are described (Appendix 3). A
sensitivity analysis was performed to estimate coverage against
the 90-90 targets if more conservative assumptions were made
(Appendix 4), in particular coverage among adolescents who did
not participate in R3. Viral load testing was not routinely done in
government clinics in Zambia; therefore, information on viral
suppression was not collected by CHiPs; the study was designed
to be similar in both countries.
Ethical approval
Ethics approval was obtained from the ethics committees of
the University of Zambia, Stellenbosch University, and the Lon-
don School of Hygiene and Tropical Medicine. Permission to
conduct the studywas received from theMinistry/Department of
Health in Zambia and SA, respectively.
Results
Participation and uptake of testing
A total of 128,241 adolescents aged 10e19 years from Zambia
and SA were enumerated by the CHiPs in the 14 communities,
95,295 in Zambia and 32,946 in SA (Figure 1). A total of 88,137
adolescents (68.7%) participated in the intervention. Participa-
tion was lower in SA, and in both countries, it was lower among
boys (Zambia: 75.9% girls vs. 68.8% boys; SA: 60.7% girls vs. 54.2%
boys; Table 1). Most adolescents who did not participate were
absent; only a small proportion refused to participate or had no
health data recorded.
Acceptance of HIV testing was higher in Zambia than SA.
Among those eligible for testing (i.e., those who did not self-
report HIV positive), 81.9% accepted testing in Zambia
compared with 70.3% in SA. There was a trend observedwith age,
with acceptance of testing increasing as age increased, but no
difference between sexes or between arms (Appendix 5).
Zambia South Africa
Figure 1. Study intervention participation and HIV testing eligibility and testing uptake among adolescents in Zambia and South Africa.
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Among participating adolescents, the number who knew
their HIV status increased substantially in both arms after R3. In
Zambia, 31.4% knew their HIV status before R3 (boys 29.2% and
girls 33.1%) compared with 88.3% after R3 (boys 87.8% and girls
88.8%). In SA, the increase was from 28.3% before (boys 21.3% and
girls 34.0%) to 79.5% after R3 (boys 77.3% and girls 81.3%; Table 1).
In both countries before R3, knowledge of HIV status was
greater among older adolescents, particularly among girls, but
after the intervention, there was little difference between boys
and girls (Figure 2). Knowledge of HIV status increased during R3
for all age groups.
Overall, therewere 1,710 known ALHIV after R3 (580 boys and
1,130 girls), of whom 1,195 (69.9%) were aware of their status and
had disclosed this, whereas 515 (30.1%) were new diagnoses
(32.3% in Zambia and 22.6% in SA). The proportion of boys knownTable 1




Participated (% among enumerated) 15,429 (66.5%) 14
Knows status when first seen in R3 (% among participants) 3,896 (25.3%) 4
Accepts testing(% among those eligible) 11,597 (76.3%) 12
Tests positive (% among those tested) 53 (.5%)
Knows status after R3 visit (% among participants) 12,788 (82.9%) 13
Known positive after R3 visit (% among participants) 276 (1.8%)
On ART when first seen in R3 (% among known positive) 203 (73.6%)
On ART at end of R3 (% among known positive and resident) 210 (86.4%)
South Africa
Enumerated 8,168 7,
Participated (% among enumerated) 4,007 (49.1%) 4
Knows status when first seen in R3 (% among participants) 497 (12.4%) 1
Accepts testing (% among those eligible) 2,558 (64.7%) 3
Tests positive (% among those tested) 4 (.2%)
Knows status after R3 visit (% among participants) 2,789 (69.6%) 3
Known positive after R3 visit (% among participants) 57 (1.4%)
On ART when first seen in R3 (% among known positive) 49 (86.0%)
On ART at end of R3 (% among known positive and resident) 52 (92.9%)
ART ¼ antiretroviral therapy.to be HIV positive among all participants was 1.5% in both
countries; among girls, the proportion was 2.2% in Zambia and
2.5% in SA (Table 1). Of the 515 new diagnoses, 335 (65.0%) were
girls aged 15e19 years. A higher proportion of 10- to 14-year-old
known ALHIV self-reported their HIV status (80.3%) compared
with 15- to 19-year-olds (63.3%).
ART coverage and time to initiate ART
ARTcoverage before R3 among self-reported ALHIVwas 90.6%
in Zambia and 84.8% in SA. Overall, ART coverage among known
ALHIV (either self-reported or tested positive with CHiPs) was
61.3% in Zambia and 65.6% in SA before R3. By the end of R3, ART
coverage had increased among known ALHIV up to 78.7% in
Zambia and 87.8% in SA. ART coverage among ALHIV who self-
reported their HIV positive status increased from 90.6% to
92.8% in Zambia and from 84.8% to 93.6% in SA. Of thestatus among ALHIV
Girls
e19 Overall 10e14 15e19 Overall
,911 44,129 25,830 25,336 51,166
,913 (71.3%) 30,342 (68.8%) 18,281 (70.8%) 20,532 (81.0%) 38,813 (75.9%)
,961 (33.3%) 8,857 (29.2%) 4,415 (24.2%) 8,425 (41.0%) 12,840 (33.1%)
,888 (87.2%) 24,485 (81.7%) 13,903 (76.9%) 17,499 (86.6%) 31,402 (82.0%)
38 (.3%) 91 (.4%) 69 (.5%) 267 (1.5%) 336 (1.1%)
,859 (92.9%) 26,647 (87.8%) 15,242 (83.4%) 19,209 (93.6%) 34,451 (88.8%)
179 (1.2%) 455 (1.5%) 273 (1.5%) 592 (2.9%) 865 (2.2%)
131 (73.2%) 334 (73.4%) 190 (69.6%) 277 (46.8%) 467 (54.0%)
133 (80.6%) 343 (84.1%) 189 (85.5%) 315 (70.5%) 504 (75.4%)
399 15,567 8,788 8,591 17,379
,425 (59.8%) 8,432 (54.2%) 4,603 (52.4%) 5,947 (69.2%) 10,550 (60.7%)
,295 (29.3%) 1,792 (21.3%) 706 (15.3%) 2,882 (48.5%) 3,588 (34.0%)
,276 (75.0%) 5,834 (70.1%) 2,911 (64.0%) 4,391 (75.6%) 7,302 (70.5%)
11 (.3%) 15 (.3%) 5 (.2%) 68 (1.5%) 73 (1.0%)
,729 (84.3%) 6,518 (77.3%) 3,212 (69.8%) 5,365 (90.2%) 8,577 (81.3%)
68 (1.5%) 125 (1.5%) 58 (1.3%) 207 (3.5%) 265 (2.5%)
47 (69.1%) 96 (76.8%) 50 (86.2%) 110 (53.1%) 160 (60.4%)
53 (88.3%) 105 (90.5%) 55 (98.2%) 150 (82.9%) 205 (86.5%)
Figure 2. Proportion of adolescents, among participants, who know their HIV status before and at the end of R3 (top two charts) and proportion of known HIV-positive
adolescent participants on ART (bottom two charts) stratified by sex and age. *Denominator for lower two plots are those known HIV þ after the R3 annual visit (so includes
newly diagnosed individuals).
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on ART in Zambia and 65% in SA at the end of R3.
In Zambia, overall ART coverage increased in boys by over 10%
and in girls by over 20%. In SA, the increases were larger; in boys,
the increase was around 14%, and in girls, it was 26% (Table 1). In
both sexes, the largest gains were seen in the older age groups
(Figure 2, lower two plots). At the end of R3, the overall percent
on ART was greater for boys than girls by almost 9% in Zambia
and 4% in SA.
The median time to ART initiation was approximately
5 months in both countries (Appendix 6). There was no evidence
to suggest a difference in time to initiate ART between sexes
(Zambia, p ¼ .25; SA, p ¼ .30) or between younger and older
adolescents (Zambia, p ¼ .11; SA, p ¼ .68).
Retention on ART
Self-reported ART retention was high in all age and sex
groups. Retention in Zambia was marginally higher at 98.2% in
boys and 94.3% in girls. In SA, retention was 92.2% in boys and
96.3% in girls.HIV treatment and care cascade
The cascade immediately before R3 by country is shown
(Figure 3). In both countries, the greatest gap, before interven-
tion, was the first step in the diagnosis of HIV infection. At each
step of the cascade, the proportions are lower for Zambia,
compared with SA.Reaching the 90-90-90 targets
At the end of R3, the first 90 target was met or nearly met in
most age groups except girls aged 13e17 years in Zambia and
those aged 15e19 years in SAwhere 83% and 84% knew their HIV
status, respectively (Figure 4).
In both countries, the second 90 was achieved or nearly ach-
ieved in adolescents aged 10e14 years. In older adolescents in
Zambia, the second 90 was not achieved, particularly in girls, with
only 76% of the 15- to 17-year-olds and 70% of the 18- to 19-year-
olds on ART. In SA, the largest gap was among 18- to 19-year-olds
with an estimated 80% on ART in both boys and girls.
Figure 3. HIV care cascade before Round 3 visit.
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conservative set of assumptions, estimates of coverage against
the first 90 target were 75%e84% for boys and 75%e83% for girls
and against the second 90 target were 73%e86% for boys and
68%e86% for girls (Appendix 7).Comparing Arms A and B
Most indicators were similar between the two intervention
arms; however, some small differences were observed in
participation and HIV status in SA. Participation in SA was
slightly higher in Arm A compared with Arm B, particularly in
girls (girls 5% higher and boys 2.2% higher). The proportion of
girls aged 15e19 years with a positive HIV diagnosis was higher
in Arm A than in Arm B in SA (3.8% vs. 3.2%). Overall, although
time to ART initiation was different by age and sex in Arm A,
there was no evidence of a difference between these groups in
Arm B. ART coverage was different between arms before R3, but
by the end of intervention, most of the difference between arms
had disappeared (Appendix 8).Figure 4. 90-90: Estimated knowledge among adolescents of HIV-positive status an
population, by age group. *Denominator for the second 90 are those known HIV þ aDiscussion
The P-ART-Y study has highlighted progress and key gaps in
delivering home-based HTS for adolescents aged 10e19 years in
SSA. We present data disaggregated by sex and age, which are
relevant from a regional perspective to enable focused and tar-
geted programmatic responses [17]. By breaking down the HIV
care cascade by age and sex, we highlight which adolescent
subpopulations require specific interventions and attention at
each stage. We also demonstrate how far we have come in terms
of achieving the first and second UNAIDS 90-90-90 targets and
what gaps remain.
We identified low knowledge of HIV status among adoles-
cents before the intervention. However, we see the substantial
impact of community-based HTS on increasing this, with more
than 80% ALHIV knowing their status in both countries after the
intervention, consistent with previous findings [18]. It also
resulted in boys and girls having similar levels of knowledge of
HIV status.
Knowledge of HIV status was considerably higher than in
other studies in SSA [19] because home-based HTS had beend ART coverage before and after the R3 intervention with extrapolation to the
fter the R3 annual visit (so includes newly diagnosed individuals).
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mately one third of adolescents were offered the intervention for
the first time during this period because of high mobility and
migration in these communities. Historically, HIV programs have
struggled to persuade adolescents to periodically test for HIV as
they often underestimate their risk [20]. The results from
adolescent surveys in SSA conducted between 2011 and 2016
showed that only 10% of boys and 12% of girls had tested for HIV
in the last 12 months [21].
Overall, the proportion of known ALHIV was comparatively
low, highlighting a window of opportunity to vigorously scale up
HIV prevention efforts [22]. In Zambia, for example, approxi-
mately 60% of YP aged 15e24 years lack correct knowledge about
HIV transmission and prevention, emphasizing the urgent need
to increase awareness [23]. Prevention services, such as pre-
exposure prophylaxis should be linked to HIV testing to maxi-
mize the additional benefit of promoting uptake [24]. For
adolescent girls and young women, tailored interventions such
as the DREAMS initiative have been shown to be effective [25].
Although most adolescents were HIV negative, we saw a
sharp increase in infection among 17- to 19-year-old girls. A high
proportion of the lifetime risk of acquiring HIV occurs in young
women is due to a complex interplay of biology, gender-power
disparities, and socioeconomic and other social triggers
affecting vulnerability in women [26,27]. In SSA, adolescent girls
aged 15e19 years are two to eight times more likely than boys of
the same age to become HIV infected [28]. Whether age-
disparate sexual partnering between older men and adolescent
girls or young women is important for HIV transmission in SSA is
still unclear [29].
The intervention came close to achieving both the first and
second 90-90-90 targets for younger boys. Gaps in the first 90
were seen in girls aged 13e17 and 15e19 years in Zambia and SA,
respectively. Recent data from 16 SSA countries indicate several
gaps in HIV testing coverage, particularly among adolescents
[30]. Population-based HIV impact assessments conducted in
Malawi, Zambia, and Zimbabwe found that only 46% of youths
(aged 15e24 years) LHIV were aware of their HIV status,
compared with 65% of 25- to 34-year-olds and 78% of 35- to
59-year-olds [31].
To achieve the 90-90-90 targets among adolescents, the main
emphasis needs to be placed on HIV testing and subsequent LTC
[32]. Recent evidence from Zambia suggests that the greatest gap
among YP aged 15e25 years is the first 90 in line with our
findings [23]. Several promising approaches such as HIV self-
testing, same-day ART initiation, differentiated models of care,
point of care CD4 count, facilitated linkage strategies, and
improved clinic services have resulted in improved outcomes
along the cascade [32e34].
Time to initiate ART was the same as for adults in the same
population [35]. However, other studies have shown worse pre-
ART and ART outcomes among adolescents compared with adults
due to a range of factors resulting in delayed ART initiation [36,37].
We saw gaps in the second 90 among older adolescents aged 15e
19 years in both countries. Data from SSA show poor ART initiation
and retention among ALHIV [38]. In the SEARCH study, only 64% of
previously diagnosed youth LHIV were on ART at baseline,
compared with 81% of older adults [38]. In this study, we put in
place several strategies to encourage LTC. These included CHiPs
escorting clients to the clinic; use of specially trained counselors;working with existing community health care workers to track
clients; following upwith clientswhomissed clinic appointments;
and holdingmeetingswith clinic staff to reviewwhich CHiP clients
had, or had not, linked to care and/or started ART.
Implementing the “treat all” strategy in SSA requires dedi-
cated efforts to address the unique needs of adolescents to
improve outcomes along the HIV care cascade. Although
provider-initiated testing plays an important role in increasing
HTS uptake, it is not sufficient on its own. Community, home, and
school-based approaches that recognize the unique needs of
adolescents are required to address the problem of undiagnosed
HIV infection among adolescents [39]. Compared with other
testing strategies, home-based HTS offers many advantages and
has been effective in enhancing testing uptake [40].
Our study had some limitations. The purpose of this study
was to report on HIV care cascade outcomes before and after the
delivery of a single round of the intervention, using data
collected as part of service delivery. However, given the possi-
bility of secular trends affecting uptake of HIV testing and ART, it
limits the strength of our conclusion. In addition, there was no
PopART intervention in the control arm, so there was no CHiPs
intervention data collected in Arm C. However, to overcome this,
at the end of R3, a cross-sectional surveywas conducted in Arm C
to provide comparative data; results have been reported else-
where (article under review). Although small differences were
observed between the two intervention trial arms, these were
minor, and the picture in the two arms was broadly similar.
Although it was a limitation that ART uptake, ART retention,
and prior HIV testing were self-reported, by the end of the
intervention, CHiPs had established good relationships and trust
with their clients and had received thorough and ongoing
training on electronic data collection, giving overall confidence in
self-reported data. Also, specifically for ART uptake, individuals
who reported being on ART were asked to produce their clinic
ART card as verification.
Information on viral suppression was not collected by CHiPs
as part of the intervention service delivery, as viral load testing
was not routinely done in Zambia.
We were not able to reach all enumerated adolescents,
especially in SA because of high rates of absenteeism. It was
challenging to find older boys at home because of their greater
involvement in income generation activities. These harder-to-
reach groups are not only absent from homes but do not
frequently attend clinics and may require alternative approaches
to engage them in HTS.
Finally, we also cannot disentangle the effects of the main
PopART intervention and the additional P-ART-Y targeted in-
terventions from the data. There was no control group of 10- to
19-year-olds who only received a “standard” PopART interven-
tion, allowing us to disentangle the specific effect of the youth-
targeted strategies.
Conclusions
The first two UNAIDS 90-90-90 targets were markedly
increased among adolescents after the delivery of a PopART
package of services, which included adolescent-specific
interventions. No opportunity to provide HIV prevention ap-
proaches to the large majority of HIV-negative adolescents
should be missed.
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